A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in
participants with locally advanced/inoperable or metastatic pancreatic cancer, and will
investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.